A
MRNA icon

Astrantus’s Moderna MRNA Stock Holding History

Astrantus’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,700
Closed -$686K – 255
2021
Q4 		$686K Buy
+2,700
New +$789K 0.51% 80

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Astrantus's MRNA Position: Q1 2022 in Review

Astrantus sold out of Moderna (MRNA) in Q1 2022, closing a stake of 2,700 shares — an estimated $686K sold.

Astrantus first reported a position in MRNA in Q4 2021 and held it in 1 quarter. The position peaked at $686K in Q4 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • Astrantus reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • Astrantus sold 2,700 Moderna shares in Q1 2022, an estimated $686K.
  • Astrantus first reported a position in Moderna in Q4 2021 and held it in 1 quarter.
  • Astrantus's Moderna position peaked at $686K in Q4 2021.
  • 1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Astrantus's 13F filing for Q1 2022, filed 11 May 2022.